147 related articles for article (PubMed ID: 15356085)
1. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide.
Ibáñez L; Valls C; Cabré S; De Zegher F
J Clin Endocrinol Metab; 2004 Sep; 89(9):4716-20. PubMed ID: 15356085
[TBL] [Abstract][Full Text] [Related]
2. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy.
Ibáñez L; de Zegher F
J Clin Endocrinol Metab; 2005 Jan; 90(1):39-43. PubMed ID: 15483105
[TBL] [Abstract][Full Text] [Related]
3. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Ibáñez L; de Zegher F
J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
[TBL] [Abstract][Full Text] [Related]
4. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism.
Ibáñez L; Ong K; Ferrer A; Amin R; Dunger D; de Zegher F
J Clin Endocrinol Metab; 2003 Jun; 88(6):2600-6. PubMed ID: 12788862
[TBL] [Abstract][Full Text] [Related]
5. Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.
Ibáñez L; De Zegher F
Hum Reprod; 2004 Aug; 19(8):1725-7. PubMed ID: 15229206
[TBL] [Abstract][Full Text] [Related]
6. Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception.
Ibáñez L; De Zegher F
J Clin Endocrinol Metab; 2003 Oct; 88(10):4720-4. PubMed ID: 14557446
[TBL] [Abstract][Full Text] [Related]
7. Divergent effects of ethinylestradiol-drospirenone and flutamide-metformin on follistatin in adolescents and women with hyperinsulinemic androgen excess.
Ibáñez L; Díaz M; López-Bermejo A; de Zegher F
Gynecol Endocrinol; 2011 Mar; 27(3):197-8. PubMed ID: 20528210
[TBL] [Abstract][Full Text] [Related]
8. Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months.
Ibáñez L; López-Bermejo A; Díaz M; Enríquez G; Del Río L; De Zegher F
Gynecol Endocrinol; 2010 Dec; 26(12):869-73. PubMed ID: 20500100
[TBL] [Abstract][Full Text] [Related]
9. Ethinyl estradiol-cyproterone acetate versus low-dose pioglitazone-flutamide-metformin for adolescent girls with androgen excess: divergent effects on CD163, TWEAK receptor, ANGPTL4, and LEPTIN expression in subcutaneous adipose tissue.
Díaz M; Chacón MR; López-Bermejo A; Maymó-Masip E; Salvador C; Vendrell J; de Zegher F; Ibáñez L
J Clin Endocrinol Metab; 2012 Oct; 97(10):3630-8. PubMed ID: 22791755
[TBL] [Abstract][Full Text] [Related]
10. Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin treatment.
Ibáñez L; Valls C; Marcos MV; Ong K; Dunger DB; De Zegher F
J Clin Endocrinol Metab; 2004 Sep; 89(9):4331-7. PubMed ID: 15356029
[TBL] [Abstract][Full Text] [Related]
11. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR
Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
[TBL] [Abstract][Full Text] [Related]
12. Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: normalizing effects on CRP, TNF-alpha and the neutrophil/lymphocyte ratio.
Ibáñez L; Valls C; de Zegher F
Hum Reprod; 2006 Feb; 21(2):451-6. PubMed ID: 16239318
[TBL] [Abstract][Full Text] [Related]
13. Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess.
Lázaro I; Díaz M; Cabré A; Masana L; Ibáñez L
Gynecol Endocrinol; 2011 Nov; 27(11):935-9. PubMed ID: 21605000
[TBL] [Abstract][Full Text] [Related]
14. Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess.
Ibáñez L; López-Bermejo A; del Rio L; Enríquez G; Valls C; de Zegher F
J Clin Endocrinol Metab; 2007 May; 92(5):1710-4. PubMed ID: 17299064
[TBL] [Abstract][Full Text] [Related]
15. The effects of drospirenone-ethinyl estradiol and drospirenone-ethinyl estradiol + metformin on ovarian ultrasonographic markers, body fat mass index, leptin, and ghrelin.
Cakiroglu Y; Vural B; Isgoren S
Arch Gynecol Obstet; 2013 Jul; 288(1):213-20. PubMed ID: 23377194
[TBL] [Abstract][Full Text] [Related]
16. Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome.
Ibáñez L; de Zegher F
Hum Reprod; 2003 Jan; 18(1):57-60. PubMed ID: 12525441
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Apelin and Insulin Resistance in Patients with PCOS and Therapeutic Effect of Drospirenone-Ethinylestradiol Plus Metformin.
Sun X; Wu X; Zhou Y; Yu X; Zhang W
Med Sci Monit; 2015 Aug; 21():2547-52. PubMed ID: 26314870
[TBL] [Abstract][Full Text] [Related]
18. The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome.
Kaya MG; Calapkorur B; Karaca Z; Yildirim S; Celik A; Akpek M; Unluhizarci K; Kelestimur F
Clin Endocrinol (Oxf); 2012 Dec; 77(6):885-92. PubMed ID: 22563947
[TBL] [Abstract][Full Text] [Related]
19. Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation.
Ibáñez L; Valls C; Ferrer A; Ong K; Dunger DB; De Zegher F
J Clin Endocrinol Metab; 2002 Jun; 87(6):2870-4. PubMed ID: 12050266
[TBL] [Abstract][Full Text] [Related]
20. Treatment of androgen excess in adolescent girls: ethinylestradiol-cyproteroneacetate versus low-dose pioglitazone-flutamide-metformin.
Ibáñez L; Diaz M; Sebastiani G; Sánchez-Infantes D; Salvador C; Lopez-Bermejo A; de Zegher F
J Clin Endocrinol Metab; 2011 Nov; 96(11):3361-6. PubMed ID: 21865363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
